ReviewNature reviews. Rheumatology2015
Perception of self: distinguishing autoimmunity from autoinflammation.
Review in Nature reviews. Rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Unveiling the dark side of glucose-regulated protein 78 (GRP78) in cancers and other human pathology: a systematic review.Molecular medicine (Cambridge, Mass.) · 2023Pooled it
- A clinical score to guide in decision making for monogenic type I IFNopathies.Pediatric research · 2020Pooled it
- 20 years of progress in the classification of immune-mediated diseases.Nature reviews. Rheumatology · 2026Article
- The signaling and regulatory functions of dying cells and cell corpses.Communications biology · 2026Review
- Oncolytic virus and immunogenic cell death in cancer therapy.Tumour virus research · 2025Review
- Single-cell transcriptional landscape of peripheral myeloid cells in autoimmune diseases.iScience · 2025Article
- Autoimmune Pericarditis: Diagnosis and New Therapeutics.Current cardiology reports · 2025Review
- Advances in the Multimodality Imaging and Management of Recurrent Pericarditis: A Contemporary Review.Current cardiology reports · 2024Review
- Exploring Bioactive Phytomedicines for Advancing Pulmonary Infection Management: Insights and Future Prospects.Phytotherapy research : PTR · 2024Review
- Recurrent Pericarditis and Paradigm Shift in Cardiovascular Imaging and Targeted Therapeutics.JACC. Advances · 2024Review
- Interleukin-1 Blockers in Recurrent and Acute Pericarditis: State of the Art and Future Directions.Medicina (Kaunas, Lithuania) · 2024Review
- Multi-Omics Approach to Improved Diagnosis and Treatment of Atopic Dermatitis and Psoriasis.International journal of molecular sciences · 2024Review
- Cytoplasmic DNA and AIM2 inflammasome in RA: where they come from and where they go?Frontiers in immunology · 2024Review
- Clinical utility of measuring CD4Journal of autoimmunity · 2023Article
- What General Neurologists Should Know about Autoinflammatory Syndromes?Brain sciences · 2023Review
- Paradigm Shift in Diagnosis and Targeted Therapy in Recurrent Pericarditis.Current cardiology reports · 2023Review
- Dysregulation of miRNA-30e-3p targeting IL-1β in an international cohort of systemic autoinflammatory disease patients.Journal of molecular medicine (Berlin, Germany) · 2023Article
- Review
- Regulation of immunological tolerance by the p53-inhibitor iASPP.Cell death & disease · 2023Article
- Optimal use of the FDG-PET/CT in the diagnostic process of fever of unknown origin (FUO): a comprehensive review.Japanese journal of radiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatic diseases can be divided in two groups, autoinflammatory and autoimmune disorders. The clinical presentation of both types of diseases overlap, but the pathological pathways underlying rheumatic autoinflammation and autoimmunity are distinct and are the subject of ongoing research. There are a number of ways in which these groups of diseases differ in terms of disease mechanisms and therapeutic responses. First, autoinflammatory diseases are driven by endogenous danger signals, metabolic mediators and cytokines, whereas autoimmunity involves the activation of T and B cells, the latter requiring V-(D)-J recombination of receptor-chain gene segments for maturation. Second, the efficacy of biologic agents directed against proinflammatory cytokines (for example IL-1β and TNF) also highlights differences between autoinflammatory and autoimmune processes. Finally, whereas autoinflammatory diseases are mostly driven by inflammasome-induced IL-1β and IL-18 production, autoimmune diseases are associated with type I interferon (IFN) signatures in blood. In this Review, we provide an overview of the monocyte intracellular pathways that drive autoinflammation and autoimmunity. We convey recent findings on how the type I IFN pathway can modulate IL-1β signalling (and vice versa), and discuss why IL-1β-mediated autoinflammatory diseases do not perpetuate into autoimmunity. The origins of intracellular autoantigens in autoimmune disorders are also discussed. Finally, we suggest how new mechanistic knowledge of autoinflammatory and autoimmune diseases might help improve treatment strategies to benefit patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.